When infections occur in the body, stem cells in the blood often jump into action by multiplying and
differentiating1 into mature immune cells that can fight off illness. But repeated infections and inflammation can
deplete2(耗尽) these cell populations, potentially leading to the development of serious blood conditions such as cancer. Now, a team of researchers led by biologists at the California Institute of Technology (Caltech) has found that, in mouse models, the
molecule3 microRNA-146a (miR-146a) acts as a critical regulator and protector of blood-forming stem cells (called
hematopoietic造血的 stem cells, or HSCs) during
chronic4 inflammation, suggesting that a deficiency of miR-146a may be one important cause of blood cancers and bone
marrow5 failure. The team came to this conclusion by developing a mouse model that lacks miR-146a. RNA is a polymer structured like
DNA6, the chemical that makes up our
genes7. MicroRNAs, as the name implies, are a class of very short RNAs that can
interfere8 with or regulate the activities of particular genes. When subjected to a state of chronic inflammation, mice lacking miR-146a showed a decline in the overall number and quality of their HSCs; normal mice producing the molecule, in contrast, were better able to maintain their levels of HSCs despite long-term inflammation. The researchers' findings are outlined in the May 21 issue of the new journal eLIFE.
"This mouse with
genetic9 deletion of miR-146a is a wonderful model with which to understand chronic-inflammation-driven
tumor10 formation and hematopoietic stem cell biology during chronic inflammation," says Jimmy Zhao, the lead author of the study and a MD/PhD student in the Caltech laboratory of David Baltimore, the Robert Andrews Millikan Professor of Biology. "It was surprising that a single microRNA plays such a crucial role. Deleting it produced a profound and dramatic pathology, which clearly highlights the critical and indispensable function of miR-146a in guarding the quality and
longevity11 of HSCs."
The study findings provide, for the first time, a
detailed12 molecular13 connection between chronic inflammation, and bone marrow failure and diseases of the blood. These findings could lead to the discovery and development of anti-inflammatory
molecules14 that could be used as therapeutics for blood diseases. In fact, the researchers believe that miR-146a itself may ultimately become a very effective anti-inflammatory molecule, once RNA molecules or mimetics can be delivered more
efficiently15 to the cells of interest.
The new mouse model, Zhao says, also
mimics16 important aspects of human myelodysplastic
syndrome17 (MDS) -- a form of pre-leukemia that often causes severe
anemia18, can require frequent blood
transfusions19, and usually leads to acute myeloid leukemia. Further study of the model could lead to a better understanding of the condition and therefore potential new treatments for MDS.
"This study speaks to the importance of keeping chronic inflammation in check and provides a good rationale for broad use of safer and more effective anti-inflammatory molecules," says Baltimore, who is a coauthor of the study. "If we can understand what cell types and proteins are critically important in chronic-inflammation-driven tumor formation and stem cell
exhaustion20, we can potentially design better and safer drugs to intervene."
Funding for the research outlined in the eLIFE paper, titled "MicroRNA-146a acts as a
guardian21 of the quality and longevity of hematopoietic stem cells in mice," was provided by the National Institute of
Allergy22 and Infectious Disease; the National Heart, Lung, and Blood Institute; and the National Cancer Institute. Yvette Garcia-Flores, the lead technician in Baltimore's lab, also contributed to the study along with Dinesh Rao from UCLA and Ryan O'Connell from the University of Utah. eLIFE, a new open-access, high-impact journal, is backed by three of the world's leading funding agencies, the Howard Hughes Medical Institute, the Max Planck Society, and the Wellcome Trust.